,121 As reviewed by Tabana et al.,120 the progress in immunotherapy for BC goes beyond the PD-1/programmed death ligand 1 (PD-L1) axis, novel targets such as stimulator of interferon genes (STING), toll-like receptors (TLRs), and colony-stimulating factors/receptor (CSF-1/CSF-1R) pathways, which hold promise for enhancing immunotherapy outcomes. The gene discussed is STING1; the disease is breast cancer.